Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zheng Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9330-0728; OpenAlex author ID A5100401133. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
52
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: 2 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: none · 2024: none · 2025: 2 papers

Papers 13

  1. NEAT1 promotes the perineural invasion of pancreatic cancer via the E2F1/GDNF axis. Co-author DOI 10.1016/j.canlet.2025.217497↗
  2. Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation. Co-author DOI 10.1016/j.intimp.2025.114528↗
  3. Editorial: The Microenvironment in Pancreatic Cancer and Therapeutic Strategies Targeting Microenvironment. First author DOI 10.3389/fonc.2022.923982↗
  4. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Last author DOI 10.7150/ijbs.72204↗
  5. ALKBH5-mediated m6A demethylation of KCNK15-AS1 inhibits pancreatic cancer progression via regulating KCNK15 and PTEN/AKT signaling. Co-author DOI 10.1038/s41419-021-04401-4↗
  6. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. Co-author DOI 10.3389/fonc.2021.728583↗
  7. Proton and carbon ion radiation therapy for locally advanced pancreatic cancer: A phase I dose escalation study. Last author DOI 10.1016/j.pan.2020.01.010↗
  8. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.01038↗
  9. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways. First author DOI 10.3892/or.2018.6833↗
  10. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validatio… Co-author DOI 10.1038/s41598-017-01904-z↗
  11. Intensity modulated radiotherapy for locally advanced and metastatic pancreatic cancer: a mono-institutional retrospective analysis. Co-author DOI 10.1186/s13014-014-0312-5↗
  12. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Last author DOI 10.18632/oncotarget.3686↗
  13. Therapeutic potential of perineural invasion, hypoxia and desmoplasia in pancreatic cancer. Co-author DOI 10.2174/13816128112092395↗

Closest collaborators

The 25 strongest of 52 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 8 shared papers, 2012–2025 · strength 0.97
  2. Weikun Qian · 4 shared papers, 2020–2025 · strength 0.67
  3. Wanxing Duan · 4 shared papers, 2015–2025 · strength 0.57
  4. Liang Han · 2 shared papers, 2019–2025 · strength 0.35
  5. Jiguang Ma · 2 shared papers, 2020–2025 · strength 0.34
  6. Erxi Wu · 3 shared papers, 2012–2022 · strength 0.32
  7. Wentong Mei · 1 shared paper, 2025 · strength 0.26
  8. Yuchen Jia · 1 shared paper, 2025 · strength 0.26
  9. Fei Li · 1 shared paper, 2025 · strength 0.26
  10. Simei Zhang · 2 shared papers, 2021–2022 · strength 0.25
  11. Zeen Zhu · 2 shared papers, 2021–2022 · strength 0.25
  12. Wunai Zhang · 2 shared papers, 2021–2022 · strength 0.25
  13. Jiantao Mo · 1 shared paper, 2025 · strength 0.25
  14. Tao Qin · 1 shared paper, 2025 · strength 0.25
  15. Jingtao Gu · 1 shared paper, 2025 · strength 0.25
  16. Zheng Wu · 3 shared papers, 2015–2022 · strength 0.24
  17. Ying Xiao · 2 shared papers, 2020–2021 · strength 0.21
  18. Tao Qin · 2 shared papers, 2020–2021 · strength 0.21
  19. Qinhong Xu · 3 shared papers, 2012–2020 · strength 0.18
  20. Shuai Wu · 1 shared paper, 2022 · strength 0.14
  21. Weifan Zhang · 1 shared paper, 2022 · strength 0.14
  22. Li Li · 1 shared paper, 2022 · strength 0.14
  23. Yangyang Yue · 1 shared paper, 2022 · strength 0.14
  24. Keping Xie · 1 shared paper, 2022 · strength 0.14
  25. Chunyang Lv · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.